Russell Investments Group Ltd. Increases Stake in SciClone Pharmaceuticals, Inc. (SCLN)

Russell Investments Group Ltd. increased its stake in shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 23.9% during the first quarter, Holdings Channel reports. The institutional investor owned 162,121 shares of the specialty pharmaceutical company’s stock after buying an additional 31,254 shares during the period. Russell Investments Group Ltd.’s holdings in SciClone Pharmaceuticals were worth $1,589,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Allianz Asset Management AG increased its stake in shares of SciClone Pharmaceuticals by 25.6% in the fourth quarter. Allianz Asset Management AG now owns 103,801 shares of the specialty pharmaceutical company’s stock valued at $1,121,000 after buying an additional 21,149 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of SciClone Pharmaceuticals by 6.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 39,519 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 2,389 shares in the last quarter. Guggenheim Capital LLC bought a new stake in shares of SciClone Pharmaceuticals during the fourth quarter valued at approximately $1,996,000. GSA Capital Partners LLP increased its stake in shares of SciClone Pharmaceuticals by 14.7% in the fourth quarter. GSA Capital Partners LLP now owns 231,214 shares of the specialty pharmaceutical company’s stock valued at $2,497,000 after buying an additional 29,701 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in shares of SciClone Pharmaceuticals by 146.3% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 107,991 shares of the specialty pharmaceutical company’s stock valued at $1,166,000 after buying an additional 64,142 shares in the last quarter. 71.80% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) opened at 10.85 on Tuesday. The stock has a market capitalization of $561.29 million, a P/E ratio of 15.26 and a beta of 1.76. SciClone Pharmaceuticals, Inc. has a 52 week low of $8.55 and a 52 week high of $13.74. The company has a 50-day moving average price of $9.92 and a 200 day moving average price of $9.98.

ILLEGAL ACTIVITY NOTICE: This report was reported by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/2654251/russell-investments-group-ltd-increases-stake-in-sciclone-pharmaceuticals-inc-scln.html.

Separately, Maxim Group reissued a “hold” rating on shares of SciClone Pharmaceuticals in a research note on Thursday, June 8th.

In other SciClone Pharmaceuticals news, CFO Wilson Wai-Shun Cheung sold 40,500 shares of SciClone Pharmaceuticals stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $10.75, for a total transaction of $435,375.00. Following the transaction, the chief financial officer now directly owns 14,372 shares in the company, valued at $154,499. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Friedhelm Blobel sold 40,000 shares of SciClone Pharmaceuticals stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $9.56, for a total value of $382,400.00. Following the transaction, the chief executive officer now owns 104,204 shares in the company, valued at $996,190.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 233,082 shares of company stock worth $2,318,084. Corporate insiders own 7.63% of the company’s stock.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:SCLN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.